Business Context and Reporting Period
Company: Amphastar Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: March 14, 2016
Reporting Period: Quarter ended December 31, 2015
This filing serves as a notification that the company issued a press release announcing its financial results for the quarter ended December 31, 2015. The press release is included as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific financial data. The filing explicitly states that the detailed results are contained in the press release (Exhibit 99.1), which is not included in the input text.
- Revenue: Not provided in filing text.
- Profit: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Margins: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. It only references the announcement of results for the quarter ended December 31, 2015.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, or specific risk factors. It includes a standard disclaimer stating that the information in the press release (Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference in other filings except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 14, 2016) for actual revenue, net income, and EPS figures.
- Verify year-over-year growth rates and margin trends in the full press release.
- Check for any forward-looking statements or guidance updates in the press release text.
- Confirm the status of any regulatory approvals or product launches mentioned in the full announcement.